Mesoblast (NASDAQ:MESO) Trading Down 4.8% – Time to Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) fell 4.8% during trading on Wednesday . The stock traded as low as $10.10 and last traded at $10.30. 44,977 shares were traded during mid-day trading, a decline of 94% from the average session volume of 759,654 shares. The stock had previously closed at $10.82.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MESO. Piper Sandler raised Mesoblast from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $4.00 to $11.00 in a research note on Tuesday, July 23rd. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Tuesday, September 24th. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. Finally, StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.50.

Mesoblast Stock Down 4.8 %

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The business has a 50-day moving average price of $8.73 and a two-hundred day moving average price of $7.64.

Institutional Investors Weigh In On Mesoblast

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its stake in shares of Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the period. Marshall Wace LLP acquired a new position in Mesoblast in the second quarter valued at about $562,000. Lazari Capital Management Inc. grew its stake in Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after acquiring an additional 3,300 shares during the period. XY Capital Ltd acquired a new position in Mesoblast in the 3rd quarter worth $244,000. Finally, Creative Planning acquired a new stake in Mesoblast in the 3rd quarter valued at approximately $147,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.